Hospitals leveraging biometrics to identify patients

Amid a major period of consolidation in the healthcare space, health systems have grown so large that using a patient’s name or date of birth is no longer a good identifier. Instead, hospitals are turning to biometric systems, which use fingerprints or other physical characteristics to identify people, The Wall Street Journal reported.

Mismatched patients with the same name and date of birth are an increasingly common problem, though mistakes in identification can also happen when information is incorrectly entered. In one Houston-based health system, nearly 3,000 women had the same name, including more than 500 who had the same date of birth.

The issue is so large that nearly one-fifth of respondents in a 2012 survey of healthcare chief information officers said there was at least one incidence where a mismatch led to patient harm in the past year, the WSJ reported.

“And the potential for mismatches has grown since then,” the paper stated.

To avoid this, hundreds of hospitals have turned to biometrics to correctly identify patients. One projection put the portion of healthcare providers using these tools at 40 percent by 2022. However, health systems need to ensure biometric integration in existing IT systems is secure. Other standards on using biometrics across the healthcare space will also need to be fleshed out as these systems continue to be more widely used.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.